<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966706</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000642240</org_study_id>
    <secondary_id>SRSI-PACT-9</secondary_id>
    <secondary_id>2005-002586-36</secondary_id>
    <nct_id>NCT00966706</nct_id>
  </id_info>
  <brief_title>Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer</brief_title>
  <acronym>PACT-9</acronym>
  <official_title>PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, capecitabine, gemcitabine&#xD;
      hydrochloride, epirubicin hydrochloride, and docetaxel, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known&#xD;
      whether cisplatin, capecitabine, and gemcitabine hydrochloride are more effective when given&#xD;
      together with epirubicin hydrochloride or docetaxel in treating patients with advanced or&#xD;
      metastatic pancreatic cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects of giving cisplatin,&#xD;
      capecitabine, and gemcitabine hydrochloride together with epirubicin hydrochloride compared&#xD;
      with giving cisplatin, capecitabine, and gemcitabine hydrochloride together with docetaxel&#xD;
      and to see how well it works in treating patients with stage III or stage IV pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess 6-months progression-free survival of patients with stage III or IV&#xD;
           adenocarcinoma of the pancreas treated with cisplatin, capecitabine, gemcitabine&#xD;
           hydrochloride (PXG) and epirubicin hydrochloride vs PXG and docetaxel.&#xD;
&#xD;
        -  Evaluate the activity and toxicity of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I (PEXG): Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on&#xD;
           days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to&#xD;
           6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (PGDX): Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin&#xD;
           hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28&#xD;
           days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients may then undergo surgery if the tumor becomes resectable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6-months</measure>
    <time_frame>every 2 months during therapy; every 3 months thereafter</time_frame>
    <description>CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>every 2 months during therapy; every 3 months thereafter</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>every 2 weeks during therapy</time_frame>
    <description>outpatient visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given systemically</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given systemically</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Cisplatino-TEVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given systemically</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>TAXOTERE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <description>Given systemically</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>FARMARUBICINA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given systemically</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the&#xD;
             pancreas&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Adequate bone marrow, liver, and kidney function&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No other malignancies within the past 5 years except surgically treated carcinoma in&#xD;
             situ of the cervix, and basal or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No multiple severe diseases that can compromise study safety, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Cardiac failure&#xD;
&#xD;
               -  Myocardial infarction within the past 4 months&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  History of psychiatric disabilities&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for pancreatic cancer&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico H. San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Michele Reni</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

